UBS AM
GBIO

UBS AM’s Generation Bio GBIO Stock Holding History

UBS AM’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,467
Closed -$96.9K – 2691
2022
Q4 		$96.9K Hold
2,467
– – ﹤0.01% 2497
2022
Q3 		$131K Hold
2,467
– – ﹤0.01% 2660
2022
Q2 		$162K Hold
2,467
– – ﹤0.01% 2603
2022
Q1 		$181K Hold
2,467
– – ﹤0.01% 2697
2021
Q4 		$175K Sell
2,467
-49
-2% -$8.55K ﹤0.01% 2781
2021
Q3 		$631K Buy
2,516
+269
+12% +$64.4K ﹤0.01% 2401
2021
Q2 		$605K Buy
2,247
+457
+26% +$137K ﹤0.01% 2455
2021
Q1 		$509K Buy
+1,790
New +$573K ﹤0.01% 2381
2020
Q3 		– Sell
-2,600
Closed -$546K – 2494
2020
Q2 		$546K Buy
+2,600
New +$579K ﹤0.01% 2088

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

UBS AM's GBIO Position: Q1 2023 in Review

UBS AM sold out of Generation Bio (GBIO) in Q1 2023, closing a stake of 2,467 shares — an estimated $96.9K sold.

UBS AM first reported a position in GBIO in Q2 2020 and held it in 9 quarters. The position peaked at $631K in Q3 2021. 83 funds tracked by Wall St. Rank hold GBIO as of Q1 2023.

  • UBS AM reported no remaining Generation Bio position as of Q1 2023 after selling out during the quarter.
  • UBS AM sold 2,467 Generation Bio shares in Q1 2023, an estimated $96.9K.
  • UBS AM first reported a position in Generation Bio in Q2 2020 and held it in 9 quarters.
  • UBS AM's Generation Bio position peaked at $631K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Generation Bio as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.